Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Computer Simulations in Biopharmaceutical Characterization and Pharmacokinetics: Enhancing Drug Development Processes

Ashwini C. Utage[1], Sanket R. Patil[1], Pradeep L. Bodake[2], Darshan V. Shah[3], Sachin S. Mali[4*], Prajakta R. Patil[4], Poonam S. Sable[5], Shivraj S. Shivpuje[6]

[1]Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India
[2]Principal, Dept. Of Pharmaceutics, S. B. Patil College Of Pharmacy, Vangali- Indapur, , Maharashtra, India
[3]Professor and Principal, Anekant Education Society's College of Pharmacy, Baramati, Maharashtra, India
[4]Ashokrao Mane College of Pharmacy, Peth-Vadgaon, Kolhapur, Maharashtra, India
[5]Srinath college of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, India
[6]School of Pharmacy, SRTM University, Nanded, Maharashtra, India
Email: sachinmali143@gmail.com

Characterization of biopharmaceuticals integrated with PK modeling by computer simulations has revolutionized the landscape of drug development, giving way to an unprecedented approach in the optimization of drug design and streamlining of discovery. These computational tools allow for virtual exploration of drug properties, behaviors, and interactions within biological systems, providing critical insight into drug ADME profiles. This review describes the most common simulation techniques - namely, molecular dynamics (MD), physiologically based pharmacokinetic (PBPK) modeling, and population PK (PopPK) modeling-whereby one describes applications, benefits, and limitations of each. MD simulations allow researchers to explain different molecular phenomena at the atomic level, with critical information on drug-receptor binding and protein conformational changes that give increased understanding into drug efficacy. PBPK modeling, on the other hand, allows one to predict drug concentration profiles in various tissues and organs using physiological, biochemical, and pharmacological data.

The model has proven to be useful for selection of appropriate dose, drug-drug interactions, and support to regulatory submissions. Population PK modeling considers variability of response between populations, focusing on individual factors such as age, genetics, and disease states to optimize dosing strategies and enhance personalized medicine approaches.

Further technological advances will enable free flows of artificial intelligence and machine learning integration into these models, making them very predictably impactful within the pharmaceutical industry.

Keywords: Molecular dynamics, physiologically based pharmacokinetic model, Drug receptor

binding, Conformational changes.

Graphical Abstract:



1. Introduction

Biopharmaceutical characterization and pharmacokinetics offer an overall view of a drug's ADME profile. It is very important because based on it, one can make a judgment about the efficacy and safety of the drugs. Traditionally, all these evaluations depend on in vitro experiments, animal studies, and clinical trials, which are time-consuming and resource-intensive. To overcome these challenges, computer simulations have become a necessary instrument. Researchers can predict the behavior of drugs in virtual environments, thereby accelerating drug development. Computer simulations allow study of molecular interactions, drug-receptor binding, and systemic behavior of drugs with the possibility of making early decisions and minimizing physical testing. A few computer simulations are typically used in drug development-one for each specific application and advantage [1].

2. Types of Computer Simulations in Drug Development

Computer simulations have been established as the foundation on which today's medicines are developed; they provide a rich source of knowledge concerning the behavior of drug molecules in biological systems. A variety of simulations can predict molecular interactions, pharmacokinetics, and drug efficacy by offering a cost-effective and efficient way in optimizing drug design and delivery. The following is a step-by-step account of the most significant types of simulations that are used in drug development[2].

2.1 Molecular Modeling and Simulations

2.1.1 Molecular Dynamics:

Molecular dynamics (MD) simulations give the atomic and molecular motion of drug compounds in time detail. MD has allowed the study of drug-receptor interactions, protein conformational changes, and stability of drug molecules in different environments [1]. MD simulations are now used in the practice of structure-based design of drugs to look at how drugs bind to their target proteins and predict the efficacy. This method is highly accurate, as it models physical movements and conformational changes of proteins upon drug binding: It's one important approach to predicting bioactivity and enhancing lead compounds [2]. A schematic

representation of how a molecular dynamics simulation is performed is shown in Fig 1.



Figure 1. Schematic Representation for simulation of Molecular dynamics

Applications:

- Evaluation of biomolecular stability and response under physiological conditions.
- Prediction of thermodynamic properties like binding affinities by free energy calculations[3].
- This includes proteins-ligand interactions that can be well interpreted to optimize leads during the discovery of drugs [4].

2.1.2 Docking Simulations:

Docking simulations predict the drug molecules' binding orientation with their target proteins. Docking is an essential component of structure-based drug design, in which researchers model how a small molecule, known as a ligand, interacts with a macromolecular target that is most often a protein to estimate the strength and stability of the binding [5]. Docking facilitates ranking of possible drugs in terms of a binding affinity and searching for promising lead compounds as early as possible in the development process. The selection criteria for protein –ligand docking is shown in Fig 2.

.



Figure 2. Method for protein-ligand docking

Applications:

- Screening large compound libraries for potential drug candidates.
- It is the understanding of the key interacting activities that facilitate ligand binding and efficacy [2].

2.2 Quantum Mechanical (QM) Simulations

QM calculations describe the electronic structure of molecules in detail, thus being able to study the stability and reactivity of drug candidates. In metabolic stability research, application of QM methods, specifically DFT, proves particularly favorable, as it facilitates prediction of the course of enzymatic transformations of drugs in the body [6]. QM simulation of the drug helps in designing drugs that are more metabolically stable and less prone to degradation. This is central for having improvements in bioavailability.

Applications:

- Prediction of Metabolic Transformations and Stability of Drug Molecules.
- Design of drugs which enter but avoid problematic metabolic pathways.

2.3 Physiologically Based Pharmacokinetic (PBPK) Modeling

The physiologically based pharmacokinetic model is even able to simulate drug ADME in a human system by using a series of connected compartments mimicked with different organs and tissues [7]. PBPK models thereafter combine physicochemical properties of the drug with physiological parameters, hence allowing for predictions of drug concentration-time profiles in different tissues. PBPK models are widely used in dose selection and drug-drug interaction

studies. They provide an important role in correlating preclinical data obtained from animals to human situations [8]. PBPK modelling depends upon anatomical and physiological data. In PBPK, organs and tissues are grouped based on their perfusion rate.

Tissues of higher perfusion like brain, kidney, lungs, liver are taken as one compartment while poorly perfused tissue like muscle, fat as another compartment. In PBPK model, important organs for ADME are included. The organs in PBPK can be defined by differential equation. For deterministic organs for blood concentration profile, such as the gut, liver, and kidney, details of mechanism are considered for the implementation of the model. In addition to this, additional tissues and organs can be included based on modeling purpose and hypothesis.



Figure 3. PBPK model

Applications:

- It produces first-in-human dose selection based on preclinical data.
- Predictability in drug interaction with enzymes and transporters, targeted to safety evaluation [7].

2.4 Population Pharmacokinetics (PopPK) Modeling

Population pharmacokinetics PopPK modeling analyses concentration variation in the response of a population of patients by exploring demographic, genetic, and physiological factors [9]. This approach uses clinical trial data to identify sources of variability across age, weight, gender, and disease state and facilitates optimization of dosing strategies across different patient groups [10].



Figure 4. Steps involved in Popk Modeling

- Data Collection: Collect data from clinical trials, observational studies, or literature.
- Model Building: Pharmacokinetic behavior of the drug is base to design the structural model. Variability is included.
- Model evaluation: diagnostic plots should be used to evaluate goodness of fit and the criteria for description.
- Validation: Validate the model with independent datasets or through cross-validation techniques.
- Clinical Application: Utilize the model to guide dosing decisions, especially for specific populations where special considerations must be made, for example, pediatrics or geriatrics.

Applications:

- Developing dosing regimens tailored to specific subgroups of patients.
- Assessing the impact of covariates such as body weight, age, and renal function on drug pharmacokinetics

2.5 In- silico Bioavailability Prediction

In-silico simulations predict a drug's bioavailability by simulating its solubility and permeability in the human body. This method is combined with the BCS to predict the rate at which a drug will be absorbed after oral administration [11]. The models facilitate pharmaceutical companies prioritizing molecules with advantageous absorption attributes for further development.

Applications:

- Predicting oral bioavailability based on drug solubility and permeability.
- Informing formulation strategies to improve absorption.

.

3. Enhancing Drug Development with Simulations

All stages from early discovery to clinical translation of drug development have a number of big advantages with computer simulations. Not only do they speed up the process, but also provide better decisions and risk assessment, since the behavior, stability, and especially the possibility of any drug interaction are told considerably by them.

3.1 Early- stage Drug Design

Lead Compound Optimization

The initial phases of drug design are optimized by MD and docking simulations to a large extent. MD simulations facilitate the atomic-level observation of how candidate molecules interact with their biological targets, thereby providing insight into the stability of drug-target complexes. The findings thus allow fine-tuning of the drug structures in order to enhance efficacy, selectivity, and pharmacokinetic properties [5]. Docking simulations are the most useful tool to predict the binding affinity or conformation of the drug candidates in the active site of receptors or enzymes. They aid in the process of drug design based on the structure, which focuses the researcher on prioritizing compounds with higher therapeutic potential [12].

3.2 Formulation Development

Predicting Drug stability and Release:

Simulations today play an important role in formulation development, especially the forecasts of stability, solubility, and release profiles of drugs. Indeed, researchers can evaluate drug degradation pathways under different environmental conditions, such as pH, temperature, and ionic strength, simulating these conditions. Moreover, models could simulate release of drugs from many dosage forms, including tables or capsules, or even transdermal patches, providing insights into the dissolution and absorption rate.

3.3 Preclinical to Clinical Translation

Humanized PBPK Model:

It is the most important tool used for translating preclinical findings into human studies. Humanized PBPK models will permit drug behavior simulation in the human organism, using factors like size of organs, blood flow, and expression of enzymes.

Thus, with such models, the animal-to-human extrapolation gap can be bridged, and they can predict first-in-human dose as well as evaluate differences between species and absorption, metabolism, and clearance [13]. PBPK models are very useful in determining the clinical trial design, thus potentially preventing unpredictable outcomes during early phases of clinical studies.

3.4 Risk Mitigation

Simulation of Drug Interaction

Drug-drug and drug-food interactions are major concerns in drug discovery, as they may constitute adverse events or reduced therapeutic efficacy. Simulations can predict possible drug-drug interactions by simulating how drugs may affect other drugs' metabolism, especially through inhibition or induction of cytochrome P450 enzymes [14].

Further, it may determine drug-food interaction, such as the influence of different foods on drug absorption and bioavailability. This can include establishing the effect of grapefruit juice on CYP3A4 activity. Early stages of the development process can offer this information regarding these interactions and thus de-risk scientific endeavors before clinical trials, hence patient safety at a later stage.

4. Key Tools and Software for Computer Simulation

4.1 Molecular Dynamic Software

Using molecular dynamics (MD) simulations, for example, one can trace motions and interactions of atoms and molecules over time. Some of the widely applied software packages are:

- GROMACS:

GROMACS is the widely used MD simulation package that was originally developed for biomolecular simulation. It can apply to the simulation of all kinds of molecular systems, from proteins and lipids to nucleic acids. GROMACS emphasizes efficiency and fastness in particularly large-scale biomolecular systems. It supports several force fields, making the GROMACS application flexible to various kinds of simulation [15].

Features:

1. Parallel architectures provide a high performance.
2. MD simulations can be thoroughly analyzed with versatile tools
3. A number of force fields and simulation protocols are supported

- AMBER:

Another very commonly used software suite for MD is AMBER, mainly concentrated on biomolecules. It offers both tools for MD simulations and for molecular modeling. Thus, it offers the perfect tool set for the study of the structure and dynamics of proteins and nucleic acids. It employs several force fields developed especially for biomolecular systems, giving very accurate calculations and simulations of energy [16].

Features:

1. Extensive support for different force fields designed for biological macromolecules.
2. Integrated tools for system preparation and analysis.
3. User-friendly interfaces to build and simulate molecular systems

- CHARMM:

CHARMM (Chemistry at HARvard Macromolecular Mechanics) is a molecular simulation package that is dedicated toward the modeling of the dynamics of biological macromolecules. It supports a wide variety of force fields, thereby providing very accurate simulations of proteins, lipids, carbohydrates, and nucleic acids. CHARMM is really good with huge

biomolecular complexes and has developed tremendous capabilities in energy minimization and molecular docking [17].

Features:

1. Flexible Force field options with nice analysis tools
2. Rich documentation and good user support.
3. Ability to perform multi-scale simulations.

Table 1: Examples of Applications Using Molecular Dynamics (MD) Software in Biopharmaceutical Characterization and Pharmacokinetics

Application Area	Description	Benefits	MD software used	References
Protein-ligand Interactions	Simulating binding interactions between drug candidates and target proteins to assess binding affinities.	Improved hit identification and optimization.	GROMACS, AMBER	Wang, Y., et al. Self-assembly of peptides: The acceleration by molecular dynamics simulations and machine learning. Nano Today. 2024 Apr 1;55:102160 .
Conformational Analysis	Exploring the conformational landscape of biopharmaceuticals to identify stable and active forms.	Enhanced understanding of drug mechanism of action.	CHARMM	Ribeiro JV., et al QwikMD—integrative molecular dynamics toolkit for novices and experts. Scientific reports. 2016 May 24;6(1):26536.
Stability Studies	Assessing the stability of protein formulations under different conditions using MD simulations.	Optimized formulation development and shelf life.	AMBER, CHARMM	Mehta CH., et al. Computational modeling for formulation design. Drug Discovery Today. 2019 Mar 1;24(3):781-8.
Enzyme Activity and Mechanism	Investigating enzyme catalysis mechanisms through simulations to identify key interactions and states.	Improved drug design targeting enzyme inhibition.	AMBER, GROMACS	Carvalho AT., et al. Challenges in computational studies of enzyme structure, function and dynamics. Journal of Molecular Graphics and Modelling. 2014 Nov 1;54:62-79.

4.2 PBPK Modeling Software

Physiologically based pharmacokinetic (PBPK) modeling helps simulate drug absorption, distribution, metabolism, and excretion in humans and animals. Some important software tools for PBPK modeling include the following

- Simcyp:

Simcyp is the name given to the well-applied PBPK modeling platform that was developed by Certara. The tool simulates drug pharmacokinetics in different populations, involving physiological, biochemical, and genetic factors. It is applied in the prediction of drug-drug interactions and evaluation of new drug formulations, and it is therefore crucial in drug development [18].

Features:

1. Extensive library of physiological parameters for different demographics
2. Tools for assessing drug interactions and virtual populations.
3. Model development graphical user interface friendly.

- GastroPlus:

GastroPlus is a PBPK modeling software that emphasizes oral drug absorption and disposition. It is another software that employs sophisticated algorithms to simulate the gastrointestinal absorption of drugs and predict plasma concentration-time profiles. GastroPlus software is typically applied in formulating drugs and virtual bioequivalence studies [19].

Features:

1. Use of in vitro and in vivo data for precise modeling.
2. Abilities to model complex absorption processes including transporters

- PK-Sim:

PK-Sim is a freeware application for PBPK modeling. PK-Sim supports simulation of drug disposition from various parts of a biological system, like from compartments. PK-Sim enables the researchers in developing population-specific models and predicts pharmacokinetic profiles according to the patients' individual characteristics. PK-Sim is part of the freeware suite of MoBi, which is intended for the modeling and simulating of biological systems [20].

Features:

1. Flexible modeling environment for developing PBPK models.
2. Generation of pharmacogenomic data for personalized medicine applications.
3. A huge database of physiological and biochemical parameters.

4.3 Population PK Models

The use of PopPK modeling is essential in understanding variability in drug responses among different patient populations. Some of the important software tools include:

- NONMEM:

NONMEM refers to the popular software with which one conducts population pharmacokinetic modeling. It's a tool designed to make an analysis of pharmacokinetic and pharmacodynamic data possible, whereby variability among individuals in clinical studies can be understood. It supports complex models and gives tools for model evaluation and comparison [21].

Features:

1. Enhances modeling capabilities related to nonlinear mixed effects analysis.
2. Enables a huge number of statistical methods to be used for data fitting.
3. Wealth of documentation and user community to support its users.

- Monolix:

Monolix is another popular PK population modeling tool, widely known for having a user-friendly interface and strong capabilities in modeling. It helps scientists to estimate and analyze complex pharmacokinetics and pharmacodynamics with nonlinear mixed-effects modeling. It supports model selection, evaluation, and simulation, and thus, this is versatile for a pharmacometrician [22].

Features:

1. Graphical interface for model development and evaluation.
2. Tools for result presentation and diagnostics.
3. Detailed documentation and user support

5 Challenges:

There are several advantages of computer simulation in drug development; however, quite a lot still remains to be done, especially in the area of data, computation, and regulatory acceptance. Therefore, it needs attention to make simulations adequately integrated into mainstream drug development and approval processes.

- Quality of experimental data:

Availability of appropriate and sufficient high-quality experimental data is one of the significant hurdles to the proper use of computer simulations for biopharmaceutical characterization and pharmacokinetics. Calibration and validation of PBPK models in particular require extensive sets of data necessary to obtain accurate simulations. This type of data set often includes a number of physiological parameters like organ sizes, blood flow rates, expression levels of enzymes, and drug-binding characteristics. In the absence of robust and reliable data, the simulations can become weak in terms of predictive strength, failing to deliver useful and actionable insights [23]. Thus, one of the most important challenges in using simulations effectively is access to consistent, high-quality experimental and clinical data, mostly for new drug entities with limited pre-existing data.

Example: The predictive performance of Simcyp or GastroPlus about drug interactions or absorption largely depends on precise pharmacokinetic data inputs. If the input data is imprecise, conclusions made from the model outputs can be wrong about drug safety or efficacy [24].

- Computational Complexity:

Another critical barrier is the computational power needed to perform such simulations. Some advanced MD simulations, such as those involving GROMACS or AMBER software, require significant computational resources, especially when simulating large biomolecular systems or over long timescales. In addition, analyses based on complex simulations typically require good knowledge in fields such as computational chemistry, biophysics, and pharmacometrics. This however places a limitation on such resources being utilized by smaller sized companies or research institutions that may lack the computing infrastructure

or expertise to use the tools [25].

Example: For instance, an extended MD simulation of a drug-receptor interaction on the GROMACS platform may consume weeks on a routine computer cluster, and the task of explaining the results to make predictions about the efficacy of a drug is an incredibly complicated challenge that calls for knowledge in molecular simulation techniques.

- Regulatory Acceptance

Acceptance of simulation-based evidence by regulatory bodies in the approval processes is also slow.

Submission frameworks for PBPK modeling data are available for use in regulatory agencies, including the FDA and the EMA; however, in-silico data are only approved to a limited extent compared to experimental data [26]. The agencies accept the possibility of PBPK modeling and other simulations, especially in drug-drug interaction studies and dose-extrapolation, but provide much resistance to using such results unless appropriately validated with experiments. This means that firms may be less likely to entrust only simulations as part of the applications for approval of drugs, and in turn, the advanced methods may go slow in implementation in the regulatory field. Example: For instance, the FDA's guidance on PBPK modeling acknowledges the benefits of such models but also underlines the importance of experimental validation in high-risk conditions like first-in-human dosing [27]. Similarly, the EMA too has promoted the submissions of PBPK data but has been careful enough not to use such information solely to make a decision [28,29].

6. Future Directions:

The future of computer simulations in drug development is definitely promising, especially with the incorporation of advanced technologies such as AI and ML[30],[31]. In the case of biopharmaceutical simulations, this will more than enhance predictability ability in pharmacokinetics and pharmacodynamics[33],[34]. AI and ML algorithms are being designed to process massive data for identifying patterns and making predictions over drug behavior that traditional models would miss. The design of drugs is another field where these tools are making it possible to do things more efficiently and in a personalized manner with real-time patient data to optimize dosages and predict outcomes with a better degree of accuracy[35],[36]. Critical in this regard has also been the inclusion of real-world evidence. Simulations can then utilize data fed from electronic health records, besides patient-reported outcomes, to produce more accurate predictions regarding a drug's performance under a vast range of patients[37],[38].

Real world evidence (RWE) thus becomes a test of simulation models under realistic conditions, thereby increasing the reliability of the models themselves, filling in the gap that already existed between clinical trials and the much broader practice of patient care. Drug safety, efficacy, and adherence all improve to a great degree for complex or long-term treatments. Regulatory agencies slowly begin to open their arms to these technologies[39,40]. The FDA, and others, are increasingly adding PBPK models and other simulations to their toolset, particularly in drug interactions, optimization of dosing, and special populations. As

acceptance grows, these simulations should become even more ubiquitous parts of the drug approval process, thereby significantly reducing the amounts of testing both in animals as well as in early-stage human subjects[41],[42]. The future holds both AI, ML, RWE, and positive regulations in an environment where the role of simulations in making drug development faster, safer, and more effective will become even stronger.

7. Conclusion

Computer simulations are rewriting the drug-development process, providing powerful tools for predicting drug behavior, optimizing formulations, and improving clinical trial designs. Such simulations really help push more efficiently through explorations of drug properties and interactions, ones that may help streamline decision-making and control costs. While the challenges associated with the lack of data, computational complexity, and acceptance by regulatory agencies remain, it is clear that emerging integration technologies involving AI and RWE will enhance the accuracy and potential for utility of these techniques.

In other words, as tools for computation advance and frameworks for regulation adapt, simulations increasingly will be at the heart of biopharmaceutical research and push the quicker, safer, and more effective processes for drug development

References

1. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nature structural biology. 2002 Sep 1;9(9):646-52.
2. Ganesan A, Coote ML, Barakat K. Molecular dynamics-driven drug discovery: leaping forward with confidence. Drug discovery today. 2017 Feb 1;22(2):249-69.
3. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. Journal of computational chemistry. 2011 Apr 15;32(5):866-77.
4. Jorgensen WL. Efficient drug lead discovery and optimization. Accounts of chemical research. 2009 Jun 16;42(6):724-33.
5. Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. Journal of chemical information and modeling. 2013 Aug 26;53(8):1893-904.
6. Cramer CJ. Essentials of computational chemistry: theories and models. John Wiley & Sons; 2013 Apr 29.
7. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics. 2015 Mar;97(3):247-62.
8. Rowland M, Peck C, Tucker G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annual review of pharmacology and toxicology. 2011 Feb 10;51(1):45-73.
9. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annual review of pharmacology and toxicology. 2000 Apr;40(1):67-95.
10. Chen ML, Amidon GL, Benet LZ, Lennernas H, Yu LX. The BCS, BDDCS, and regulatory guidances. Pharmaceutical research. 2011 Jul; 28:1774-8.

11. Mali Sachin S. et al., Development of Floating Microspheres of Anti-Ulcer drug As a Gastroretentive Drug Delivery System. Der Pharmacia Lettre, 2015, 7 (7):364-377. ISSN: 0975-5071.
12. Sachin S. Mali et al., 'Extraction and characterization of mucilage from Lepidium sativum Linn. Seeds'. Der Pharmacia Lettre. 6(1): 65-70, 2014. [ISSN 0975- 5071].Peer reviewed. https://www.scopus.com/sourceid/19700200724
13. Mali Sachin S.et al., To enhance the physicochemical properties of metoprolol succinate by co-crystal technique. Research J. Pharm. and Tech. 2017; 10(11): 3761-3767. https://doi.org/10.5958/0974-360X.2017.00683.7 ISSN No. 0974-3618 (Print) and 0974-360X (Online) © RJPT All right reserved.
14. Sachin S. Mali et al., Pelletization Technology: Methods and Applications A Review. Research J. Pharm. and Tech.8 (2): February 2015. ISSN 0974-3618 https://doi.org/10.5958/0974-360X.2015.00023.2
15. Mali Sachin S.et al., Project writing for Retail Pharmacy Practical Training: A Proforma. Research J. Pharm. and Tech. 7(9): September 2014. [ISSN 0974- 3618] https://www.scopus.com/sourceid/21100197160?dgcid=sc_widget_citescore
16. Sachin S. Mali et al., Narrative Review: A Rational Approach to Needle Free Insulin Technology, Research J. Pharm. and Tech.7(4): April 2014. [ISSN 0974-3618] IC Value 5.01. Peer reviewed. https://rjptonline.org/AbstractView.aspx?PID=2014-7-4-8
17. Mali Sachin S.et al., In silico exploration of flavonoids against bacterial TEM-1 beta-lactamase. Tuijin Jishu/Journal of Propulsion Technology. ISSN: 1001-4055 Vol. 44 No. 5, 2023. https://doi.org/10.52783/tjjpt.v44.i5.3528
18. Sachin S. Mali et al., Unveiling Nature's Arsenal: Virtual Screening of Phytoconstituents For Anti- Acne Potentials In Medicinal Plants. Nanotechnology Perceptions Volume 20 Issue No. 6 (2024) Page 1845-1860 Published Nov 5, 2024 [ISSN 1660-6795] Publisher: Brookfield Academic Limited, United Kingdom (IF 2024:0.6)
19. Mali Sachin S.et al., Enhancing Probiotic Efficacy through Progress in Polysaccharide-Based Oral Delivery Systems. Nanotechnology Perceptions Volume 20 Issue No. 6 (2024) Published Nov 5, 2024 [ISSN 1660-6795] Publisher: Brookfield Academic Limited, United Kingdom (IF 2024:0.6)
20. Kerrigan JE. Molecular dynamics simulations in drug design. In silico models for drug discovery. 2013:95-113.
21. Salahshoori I, Golriz M, Nobre MA, Mahdavi S, Malekshah RE, Javdani-Mallak A, Jorabchi MN, Khonakdar HA, Wang Q, Mohammadi AH, Mirnezami SM. Simulation-based approaches for drug delivery systems: navigating advancements, opportunities, and challenges. Journal of Molecular Liquids. 2023 Dec 27:123888.
22. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30, 2002). AAPS PharmSci. 2004 Mar;6:56-67.
23. Isoherranen N, Foti RS. In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. InIdentification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters 2020 Jan 1 (pp. 273-309).
24. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. Journal of computational chemistry. 2005 Dec;26(16):1701-18.
25. Case DA, Aktulga HM, Belfon K, Ben-Shalom I, Brozell SR, Cerutti DS, Cheatham III TE, Cruzeiro VW, Darden TA, Duke RE, Giambasu G. Amber 2021. University of California, San Francisco; 2021 Jun 13.
26. Brooks BR, Brooks III CL, Mackerell Jr AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A. CHARMM: the biomolecular simulation program. Journal of computational chemistry. 2009 Jul 30;30(10):1545-614.

27. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics. 2015 Mar;97(3):247-62.
28. Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ. Physiologically based pharmacokinetic modeling in lead optimization. 1. Evaluation and adaptation of gastroplus to predict bioavailability of medchem series. Molecular pharmaceutics. 2018 Jan 16;15(3):821-30.
29. Wang W, Ouyang D. Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery. Drug Discovery Today. 2022 Aug 1;27(8):2100-20.
30. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. Journal of pharmacokinetics and pharmacodynamics. 2003 Dec; 30:387-404.
31. Nguyen TM, Ngo TH, Truong AQ, Vu DH, Le DC, Vu NB, Can TN, Nguyen HA, Phan TP, Bambeke FV, Vidaillac C. Population pharmacokinetics and dose optimization of ceftazidime and imipenem in patients with acute exacerbations of chronic obstructive pulmonary disease. Pharmaceutics. 2021 Mar 27;13(4):456.
32. Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clinical Pharmacology & Therapeutics. 2015 Mar;97(3):247-62.
33. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, Song P, Brar SS, Madabushi R, Wu TC, Booth BP. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clinical Pharmacology & Therapeutics. 2011 Feb;89(2):259-67.
34. Sachin S. Mali et al., Phytochemical screening and in vitro antioxidant potential of Memecylon umbellatumburm leaf extracts'. Journal of Drug Delivery & Therapeutics.4(2): 30-35, 2014. [ISSN: 2250- 1177]. Impact factor 0.402, Peer reviewed. https://doi.org/10.22270/jddt.v4i2.788 and https://abcdindex.com/Journal/Journal-of-Drug-Delivery-and-Therapeutics-2250-1177
35. Sachin S. Mali et al., A review on development of biorelevant dissolution medium".Journal of Drug Delivery & Therapeutics; 2014, 4(2), 140-148.[ISSN 2250-1177]. https://doi.org/10.22270/jddt.v4i2.800
36. Sachin S. Mali et al., Sterile parenteral products: a narrative approach. Journal of Drug Delivery & Therapeutics. 2015; 5(1). ISSN: 2250-1177. https://doi.org/10.22270/JDDT.V5I1.1047
37. Sachin S. Mali et al., Design and evaluation of control release matrix tablet on diabetis mellitus by direct compression method. Journal of clin. Otorhino, head and neck surgery, vol. 27 issue 2, 2023. ISSN: 2096-7993 https://abcdindex.com/Journal/head-and-neck-journal-for-the-sciences-and-specialties-of-the-head-and-neck-1097-0347
38. Sachin S. Mali et al., A Survey: The Signs, Side Effects, Causes And Medicines For Alzheimer's Sickness. Journal Of Electronics Information Technology Science And Management. VOLUME 12, ISSUE 10, 2022. https://doi.org/10.37896/JEISMV12.10/134 https://jeitsm.com/vol-12-issue-10-2022/ ISSN NO : 0258-7982
39. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE. Biomolecular simulation: a computational microscope for molecular biology. Annual review of biophysics. 2012 Jun 9;41(1):429-52.
40. Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metabolism and Disposition. 2015 Nov 1;43(11):1823-37.
41. Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, Raines K, Zhao Y, Wang M, Lin HP, Duan J. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the US Food and Drug Administration for new drugs.

The AAPS Journal. 2021 Mar; 23:1-4.
42. Nordmark A. EMA draft Guideline on the qualification and reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation. Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development. 2017.
43. MRP Rao, S Taktode, SS Shivpuje, S Jagtap. Optimization of Transmucosal Buccal Delivery of Losartan Potassium using Factorial Design. Indian Journal of Pharmaceutical Education and Research, 2016; 50(2): S132-S139.
44. N Patre, S Patwekar, S Dhage, S Shivpuje. Formulation & Evaluation Of Piroxicam Bionanocomposite For Enhancement of Bioavailability. European Journal of Molecular & Clinical Medicine, 2020; 7(11): 9362-9376.
45. SJ Wadher, SL Patwekar, SS Shivpuje, SS Khandre, SS Lamture. Stability Indicating Assay Methods for Simultaneous Estimation of Amoxicillin Trihydrate And Cloxacillin Sodium in Combined Capsule Dosage Form by UV-Spectrophotometric Method. European Journal of Biomedical and Pharmaceutical sciences, 2017; 4(10): 858-864.
46. Santosh A. Payghan Shivraj S. Shivpuje Shailesh L. Patwekar, Karna B. Khavane, Padmavati R. Chainpure. A Review on Different Preparation Method Used For Development of Curcumin Nanoparticles. International Journal of Creative Research Thoughts, 2021;9(1):4088-4101.
47. Zeba Ashfaq Sheikh P. R. Chainpure, S. L. Patwekar, S. S. Shivpuje. Formulation and evaluation of Garciniacambogia and Commiphoramukul Herbal tablets used for AntiObesity. International Journal of Engineering, Science and Mathematics, 2019; 8(4): 180-195.
48. Pravin P Karle, Shashikant C Dhawale, Vijay V Navghare, Shivraj S Shivpuje. Optimization of extraction conditions and evaluation of Manilkara zapota (L.) P. Royen fruit peel extract for in vitro α-glucosidase enzyme inhibition and free radical scavenging potential. Future Journal of Pharmaceutical Sciences, 2021; 7(1):1-10.
49. Sheetal Rathod P. R. Chainpure, S. L. Patwekar, S. S. Shivpuje. A Study Of Carica Papaya Concerning It's Ancient And Traditional Uses - Recent Advances And Modern Applications For Improving The Milk Secretion In Lactating Womens. International Journal of Research, 2019;8(2):1851-1861.
50. Shivraj S. Shivpuje Shailesh J. Wadher, Bhagwan B. Supekar. Development And Validation Of New Ft-Ir Spectrophotometric Method For Simultaneous Estimation Of Ambroxol Hydrochloride And Cetirizine Hydrochloride In Combined Pharmaceutical. International Research Journal of Pharmacy, 2019; 10(3):110-114.
51. Shivraj S. Shivpuje, Shailesh J. Wadher, Bhagwan B. Supekar. Simultaneous Estimation of Ambroxol Hydrochloride and Cetirizine Hydrochloride in Combined Solid Tablet Formulations by HPTLC- Densitometric Method. Asian Journal of Biochemical and Pharmaceutical Research, 2019; 9(1):1-10.
52. JW Sailesh, SS Shivraj, SI Liyakat. Development and Validation of Stability Indicating RP-HPLC Method for the Estimation of Simvastatin in Bulk and Tablet Dosage form. Research Journal of Pharmacy and Technology, 2018; 11(4): 1553-1558.
53. Patil S. S. Shivpuje Shivraj S. Patre Narendra G. Development and Validation Of Stability Indicating HPTLC Method For Determination of Nisoldipine (Niso) In Tablet Dosage Form. European Journal of Biomedical and Pharmaceutical sciences, 2017; 4(12):462468.
54. W Shailesh, K Tukaram, S Shivraj, L Sima, K Supriya. Development and Validation of Stability Indicating UV Spectrophotometric Method for Simultaneous Estimation of Amoxicillin Trihydrate and Metronidazole In Bulk And In-House Tablet. World Journal of Pharmaceutical and Medical Research, 2017;3(8):312-318.
55. J Wadher Shailesh, M Kalyankar Tukaram, S Shivpuje Shivraj. Development and Validation of Stability Indicating Assay Method for Simultaneous Estimation of Amoxicillin Trihydrate and Cloxacillin Sodium In Pharmaceutical Dosage Form By Using RP-HPLC. World Journal of Pharmaceutical Research, 2017; 10(6):1002-1006.

56. Shital S. Sangale, Priyanka S. Kale, Rachana B. Lamkane, Ganga S. Gore, Priyanka B. Parekar, Shivraj S. Shivpuje (2023). Synthesis of Novel Isoxazole Derivatives as Analgesic Agents by Using Eddy's Hot Plate Method. South Asian Res J Pharm Sci, 5(1): 18-27.
57. Priyanka B. Parekar, Shivraj S. Shivpuje, Vijay V. Navghare, Manasi M. Savale, Vijaya B. Surwase, Priti S. Mane- Kolpe, Priyanak S. Kale. Polyherbal Gel Development And Evaluation For Antifungal Activity, European Journal of Molecular & Clinical Medicine. 2022; 9(03): 5409-5418.
58. Jain AA, Mane-Kolpe PD, Parekar PB, Todkari AV, Sul KT, Shivpuje SS. Brief review on Total Quality Management in Pharmaceutical Industries, International Journal of Pharmaceutical Research and Applications. 2022; 7(05):1030-1036.
59. Sumaiyya. K. Attar, Pooja P. Dhanawade, Sonali S. Gurav , Prerna H. Sidwadkar , Priyanka B. Parekar, Shivraj S. Shivpuje. Development and Validation of UV Visible Spectrophotometric Method for Estimation of Fexofenadine Hydrochloride in Bulk and Formulation, GIS SCIENCE JOURNAL. 2022; 9(11): 936-944.
60. Sumayya Kasim Atar, Priyadarshini Ravindra Kamble, Sonali Sharad Gurav, Pooja Pandit Dhanawade, Priyanka Bhanudas Parekar, Shivraj Sangapa Shivpuje. Phytochemical Screening, Physicochemical Analysis of Starch from Colocasia Esculenta, NeuroQuantology, 2022; 20(20): 903-917.
61. Priti D.Mane-Kolpe, Alfa A. Jain, Tai P. Yele, Reshma B. Devkate, Priyanka B. Parekar, Komal T. Sul, Shivraj S. Shivpuje. A Systematic Review on Effects of Chloroquine as a Antiviral against Covid-19, International Journal of Innovative Science and Research Technology, 2022;7(11): 989-995.
62. Dr. Rohit Jadhav, Prof. Abhay D. Kale, Dr. Hitesh Vishwanath Shahare, Dr. Ramesh Ingole, Dr Shailesh Patwekar, Dr S J Wadher, Shivraj Shivpuje. Molecular Docking Studies and Synthesis of Novel 3-(3- hydroxypropyl)-(nitrophenyl)[1,3] thiazolo [4,5-d] pyrimidin2(3H)-one as potent inhibitors of P. Aeruginosa of S. Aureus, Eur. Chem. Bull. 2023; 12(12): 505-515.
63. Priyanka B. Parekar, Savita D. Sonwane, Vaibhav N. Dhakane, Rasika N. Tilekar, Neelam S. Bhagdewani, Sachin M. Jadhav, Shivraj S. Shivpuje, Synthesis and Biological Evaluationof Novel 1,3,4-Oxadiazole Derivatives as Antimicrobial Agents, Journal of Cardiovascular Disease Research, 2023; 14(8):611-624.
64. Kavita R. Mane, Prachi A. Ghadage, Aishwarya S. Shilamkar, Vaishnavi A. Pawar, Sakshi B. Taware, Priyanka B. Parekar, Shivraj S. Shivpuje. Phytochemical Screening, Extraction and In-vivo study of Immunomodulation effect of Withania somnifera, Momordicadioica and Annonasqumosa leaves. Journal of Cardiovascular Disease Research, 2023; 14(9): 231-241.
65. Harshada S. Deshmukh, Vishal B. Babar, Prajkta S. Jagtap, Rupendra V. Doshi, Shivarti V. Deokate, Ashwini V. Todkari, Amrata S. Mantri, Priyanka B. Parekar, Shivraj Shivpuje (2024). A Comprehensive Review Article on Herbal Cosmetics. South Asian Res J Pharm Sci, 6(3): 50-68.